Yan Dai

Dr. Yan Dai

orcid
doxorubincin induced cardiomyopathy through inflammation, ef...

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2023 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
SSSaixian Shi
Saixian Shi
YCYe Chen
Ye Chen
ZLZhijian Luo
Zhijian Luo
GNGuojun Nie
Guojun Nie
YDYan Dai
Yan Dai
Doxorubicin (DOX) is a powerful and commonly used chemotherapeutic drug, used alone or in combination in a variety of cancers, while it has been found to cause serious cardiac side effects in clinical application. More and more researchers are trying to explore the molecular mechanisms of DOX-induced cardiomyopathy (DIC), in which oxidative stress and inflammation are considered to play a significant role. This review summarizes signaling pathways related to oxidative stress and inflammation in DIC and compounds that exert cardioprotective effects by acting on relevant signaling pathways, including the role of Nrf2/Keap1/ARE, Sirt1/p66Shc, Sirt1/PPAR/PGC-1α signaling pathways and NOS, NOX, Fe2+signaling in oxidative stress, as well as the role of NLRP3/caspase-1/GSDMD, HMGB1/TLR4/MAPKs/NF-κB, mTOR/TFEB/NF-κB pathways in DOX-induced inflammation. Hence, we attempt to explain the mechanisms of DIC in terms of oxidative stress and inflammation, and to provide a theoretical basis or new idea for further drug research on reducing DIC.

21 October 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YCYe Chen
Ye Chen
SSSaixian Shi
Saixian Shi
YDYan Dai
Yan Dai
Doxorubicin (DOX), as a kind of chemotherapy agent with remarkable therapeutic effect, can be used to treat diverse malignant tumors clinically. Dose-dependent cardiotoxicity is the most serious adverse reaction after DOX treatment, which eventually leads to cardiomyopathy and greatly limits the clinical application of DOX. DOX-induced cardiomyopathy is not a result of a single mechanistic action, and multiple mechanisms have been discovered and demonstrated experimentally, such as oxidative stress, inflammation, mitochondrial damage, calcium homeostasis disorder, ferroptosis, autophagy and apoptosis. Dexrazoxane (DEX) is the only protective agent approved by FDA for the treatment of DOX cardiomyopathy, but its clinical treatment still has some limitations. Therefore, we need to find other effective therapeutic drugs as soon as possible. In this paper, the drugs that effectively improve cardiomyopathy in recent years are mainly described from the aspects of natural drugs, endogenous substances, new dosage forms, herbal medicines, chemical modification and marketed drugs. The aim of the present study is to evaluate the effects of these drugs on DOX-induced anticancer and cardiomyopathy curative effects, so as to provide some reference value for clinical treatment of DOX-induced cardiomyopathy in the future.

1 July 2019 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
ZLZhijian Luo
Zhijian Luo
MLMingxing Li
Mingxing Li
MZMeiling Zhou
Meiling Zhou
HLHuayun Li
Huayun Li
YCYouyou Chen
Youyou Chen
YDYan Dai
Yan Dai

31 March 2023 in Cellular Signalling
Verified
Journal Article
Closed access
BTBin Tang
Bin Tang
ZLZhijian Luo
Zhijian Luo
RZRong Zhang
Rong Zhang
DZDongmei Zhang
Dongmei Zhang
GNGuojun Nie
Guojun Nie
YDYan Dai
Yan Dai

1 November 2021 in Ultrasound in Medicine & Biology
Verified
Journal Article
Closed access
ZLZhijian Luo
Zhijian Luo
YLYulu Liu
Yulu Liu
ZTZiyi Tang
Ziyi Tang
JLJialing Liu
Jialing Liu
XXXuemei Xu
Xuemei Xu
YDYan Dai
Yan Dai

9 January 2025 in Journal of Diabetes
Verified
Journal Article
Open access
SSSaixian Shi
Saixian Shi
XLXiaofeng Li
Xiaofeng Li
YCYe Chen
Ye Chen
JLJiahao Li
Jiahao Li
YDYan Dai
Yan Dai
Objective: Provide an evidence‐based basis for the selection of cardiovascular benefit drugs in Type 2 diabetes mellitus (T2DM) patients with cardiovascular disease (CVD).Methods: Conduct a comprehensive search of all relevant literature from PubMed, Embase, Web of Science, Cochrane Library, and Clinical Trials.gov from their establishment until December 13, 2023, and select randomized controlled trials (RCTs) that meet the pre‐established inclusion and exclusion criteria. Use the Cochrane bias risk assessment tool to evaluate the quality of the included literature. Use R 4.3.2 software to conduct network meta‐analysis for drug category comparison.Results: A total of 24 large‐scale randomized controlled trials (RCTs) were included, including 19 intervention measures, and 172 803 patients participated in the study. The results of the network meta‐analysis show that: GLP1RA (OR 0.89, 95% CI 0.81–0.97) and SGLT2i (OR 0.91, 95% CI 0.83–0.99) can reduce the occurrence of major adverse cardiovascular events (MACE), GLP1RA (OR 0.88, 95% CI 0.79–0.97) and SGLT2i (OR 0.89, 95% CI 0.81–0.99) reduced the risk of cardiovascular death. SGLT2i (OR 0.68, 95% CI 0.62–0.75) reduced the occurrence of hospitalization for heart failure, GLP1RA (OR 0.88, 95% CI 0.81–0.97) and SGLT2i (OR 0.89, 95% CI 0.80–0.97) reduced the occurrence of all‐cause death.Conclusion: In the comparison of new hypoglycemic drug classes, GLP1RA and SGLT2i reduced MACE, cardiovascular mortality and all‐cause mortality in T2DM patients with CVD, with no significant difference in efficacy, and DPP4i was noninferior to placebo. Only GLP1RA reduced the risk of nonfatal stroke, and only SGLT2i reduced the risk of HHF.